Australian doctors are hoping a possible new cancer drug to treat an aggressive form of leukemia in children will be a success.
There are few treatments for children diagnosed with a relapsing type of leukaemia, a blood cancer, known as T-Cell acute lymphoblastic leukaemia (T-ALL).
A study from the Children's Cancer Institute in Sydney has involved testing the new drug on mice injected with cancer cells from children with T-ALL.
The drug is called PR-1042, and so far had been very successful in lab tests, but the next stage in its development would be getting a clinical trial approved, the Australian Broadcasting Corporation reported on Friday.
The Standard Group Plc is a multi-media organization with investments in media
platforms spanning newspaper print
operations, television, radio broadcasting, digital and online services. The
Standard Group is recognized as a
leading multi-media house in Kenya with a key influence in matters of national
and international interest.